Fortunately, he said, the results of such a study, the ongoing DAPT trial, should be available in about a year. This is a 15,000-patient clinical trial in which all stent recipients were placed on DAPT for 1 year, then randomized to come off of DAPT at that point or continue on, noted Dr. Antman, professor of medicine at Harvard Medical School, Boston.
The PARIS registry is funded by Bristol-Myers Squibb and Sanofi-Aventis. Dr. Mehran reported receiving consulting fees from Sanofi-Aventis and more than half a dozen other pharmaceutical and device companies.
Simultaneous with her presentation of the PARIS registry findings in Amsterdam, the results were published online in the Lancet (Sept. 1, 2013 [doi:10.1016/50140-6736(13)61720-1]).
The study was funded by Bristol-Myers Squibb and Sanofi-Aventis. The presenter is a paid consultant to Sanofi-Aventis and other companies.